NOVAVAX INC (NVAX) Stock Fundamental Analysis
USA - NASDAQ:NVAX - US6700024010 - Common Stock
7.44 USD
+0.33 (+4.64%)
7.45 USD
+0.01 (+0.13%)
NVAX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. There are concerns on the financial health of NVAX while its profitability can be described as average. NVAX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
NVAX had positive earnings in the past year.
NVAX had a negative operating cash flow in the past year.
NVAX had negative earnings in each of the past 5 years.
NVAX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
NVAX has a Return On Assets of 31.64%. This is amongst the best in the industry. NVAX outperforms 98.49% of its industry peers.
NVAX has a better Return On Equity (1123.78%) than 99.81% of its industry peers.
NVAX has a better Return On Invested Capital (30.55%) than 98.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.64% | ||
| ROE | 1123.78% | ||
| ROIC | 30.55% |
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 39.20%, NVAX belongs to the best of the industry, outperforming 97.18% of the companies in the same industry.
With an excellent Operating Margin value of 33.97%, NVAX belongs to the best of the industry, outperforming 97.55% of the companies in the same industry.
With an excellent Gross Margin value of 88.30%, NVAX belongs to the best of the industry, outperforming 89.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.97% | ||
| PM (TTM) | 39.2% | ||
| GM | 88.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NVAX is creating value.
NVAX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NVAX has more shares outstanding
Compared to 1 year ago, NVAX has a worse debt to assets ratio.
2.2 Solvency
NVAX has an Altman-Z score of -1.87. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
NVAX has a Altman-Z score of -1.87. This is comparable to the rest of the industry: NVAX outperforms 52.17% of its industry peers.
A Debt/Equity ratio of 5.93 is on the high side and indicates that NVAX has dependencies on debt financing.
The Debt to Equity ratio of NVAX (5.93) is worse than 82.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.93 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.87 |
ROIC/WACC3.53
WACC8.65%
2.3 Liquidity
A Current Ratio of 2.36 indicates that NVAX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.36, NVAX is doing worse than 69.87% of the companies in the same industry.
NVAX has a Quick Ratio of 2.34. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.34, NVAX is not doing good in the industry: 68.17% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.34 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 165.04% over the past year.
The Revenue for NVAX has decreased by -30.65% in the past year. This is quite bad
The Revenue has been growing by 105.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)165.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.47%
Revenue 1Y (TTM)-30.65%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-16.64%
3.2 Future
Based on estimates for the next years, NVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.91% on average per year.
The Revenue is expected to decrease by -10.46% on average over the next years. This is quite bad
EPS Next Y241%
EPS Next 2Y46.07%
EPS Next 3Y26.3%
EPS Next 5Y19.91%
Revenue Next Year55.73%
Revenue Next 2Y-19.75%
Revenue Next 3Y-25.15%
Revenue Next 5Y-10.46%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 5.06 indicates a rather cheap valuation of NVAX.
Compared to the rest of the industry, the Price/Earnings ratio of NVAX indicates a rather cheap valuation: NVAX is cheaper than 99.25% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.35. NVAX is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 33.73, NVAX can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, NVAX is valued cheaply inside the industry as 90.77% of the companies are valued more expensively.
NVAX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 33.72, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.06 | ||
| Fwd PE | 33.73 |
4.2 Price Multiples
99.44% of the companies in the same industry are more expensive than NVAX, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.01 |
4.3 Compensation for Growth
NVAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NVAX's earnings are expected to grow with 26.30% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y46.07%
EPS Next 3Y26.3%
5. Dividend
5.1 Amount
NVAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.44
+0.33 (+4.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners58.63%
Inst Owner Change-0.35%
Ins Owners0.41%
Ins Owner Change5.45%
Market Cap1.21B
Revenue(TTM)682.16M
Net Income(TTM)422.82M
Analysts73.33
Price Target14.28 (91.94%)
Short Float %30.92%
Short Ratio8.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)567.42%
Min EPS beat(2)306.88%
Max EPS beat(2)827.96%
EPS beat(4)3
Avg EPS beat(4)270.61%
Min EPS beat(4)-58.31%
Max EPS beat(4)827.96%
EPS beat(8)5
Avg EPS beat(8)107.83%
EPS beat(12)7
Avg EPS beat(12)52.48%
EPS beat(16)7
Avg EPS beat(16)-6.86%
Revenue beat(2)2
Avg Revenue beat(2)74.3%
Min Revenue beat(2)58.52%
Max Revenue beat(2)90.08%
Revenue beat(4)4
Avg Revenue beat(4)40.88%
Min Revenue beat(4)2.61%
Max Revenue beat(4)90.08%
Revenue beat(8)5
Avg Revenue beat(8)18.46%
Revenue beat(12)7
Avg Revenue beat(12)18.88%
Revenue beat(16)7
Avg Revenue beat(16)2.76%
PT rev (1m)5.38%
PT rev (3m)-5.77%
EPS NQ rev (1m)-118.6%
EPS NQ rev (3m)-138.4%
EPS NY rev (1m)-3.5%
EPS NY rev (3m)-4.25%
Revenue NQ rev (1m)-24.31%
Revenue NQ rev (3m)-57.42%
Revenue NY rev (1m)-0.82%
Revenue NY rev (3m)4.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.06 | ||
| Fwd PE | 33.73 | ||
| P/S | 1.12 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 32.12 | ||
| P/tB | N/A | ||
| EV/EBITDA | 1.01 |
EPS(TTM)1.47
EY19.76%
EPS(NY)0.22
Fwd EY2.96%
FCF(TTM)-3.91
FCFYN/A
OCF(TTM)-3.88
OCFYN/A
SpS6.64
BVpS0.23
TBVpS-0.46
PEG (NY)0.02
PEG (5Y)N/A
Graham Number2.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.64% | ||
| ROE | 1123.78% | ||
| ROCE | 38.67% | ||
| ROIC | 30.55% | ||
| ROICexc | 86.37% | ||
| ROICexgc | 130.29% | ||
| OM | 33.97% | ||
| PM (TTM) | 39.2% | ||
| GM | 88.3% | ||
| FCFM | N/A |
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.93 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.55 | ||
| Cap/Depr | 11.6% | ||
| Cap/Sales | 0.44% | ||
| Interest Coverage | 18.14 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.34 | ||
| Altman-Z | -1.87 |
F-Score6
WACC8.65%
ROIC/WACC3.53
Cap/Depr(3y)158.98%
Cap/Depr(5y)408.8%
Cap/Sales(3y)4.02%
Cap/Sales(5y)5.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)165.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.47%
EPS Next Y241%
EPS Next 2Y46.07%
EPS Next 3Y26.3%
EPS Next 5Y19.91%
Revenue 1Y (TTM)-30.65%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-16.64%
Revenue Next Year55.73%
Revenue Next 2Y-19.75%
Revenue Next 3Y-25.15%
Revenue Next 5Y-10.46%
EBIT growth 1Y228.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year310.32%
EBIT Next 3Y13.97%
EBIT Next 5YN/A
FCF growth 1Y13.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.53%
OCF growth 3YN/A
OCF growth 5YN/A
NOVAVAX INC / NVAX FAQ
Can you provide the ChartMill fundamental rating for NOVAVAX INC?
ChartMill assigns a fundamental rating of 4 / 10 to NVAX.
Can you provide the valuation status for NOVAVAX INC?
ChartMill assigns a valuation rating of 6 / 10 to NOVAVAX INC (NVAX). This can be considered as Fairly Valued.
How profitable is NOVAVAX INC (NVAX) stock?
NOVAVAX INC (NVAX) has a profitability rating of 5 / 10.
How financially healthy is NOVAVAX INC?
The financial health rating of NOVAVAX INC (NVAX) is 3 / 10.